Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.39 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3126217 | 0.80 | HTR2A (0.42) | BCL2BCL2L1ALOX5HTR2AKEAP1 | |
| SCHEMBL721135 | 0.78 | CALM1 (0.44) | BCL2BCL2L1ALOX5HTR2AKEAP1 | |
| SCHEMBL28763236 | 0.77 | BCL2 (0.42) | BCL2BCL2L1ALOX5HTR2AKEAP1 | |
| SCHEMBL7463754 | 0.76 | HTR2A (0.42) | BCL2BCL2L1ALOX5HTR2AKEAP1 | |
| SCHEMBL6978264 | 0.76 | HTR2A (0.42) | BCL2BCL2L1ALOX5HTR2AKEAP1 | |
| SCHEMBL2410994 | 0.76 | HTR2A (0.42) | BCL2BCL2L1ALOX5HTR2ACALM1 | |
| SCHEMBL8204656 | 0.76 | HTR2A (0.47) | BCL2BCL2L1ALOX5HTR2ACALM1 | |
| SCHEMBL921223 | 0.76 | HTR2A (0.42) | BCL2BCL2L1ALOX5HTR2AKEAP1 | |
| SCHEMBL5796035 | 0.74 | HTR2A (0.41) | BCL2BCL2L1ALOX5HTR2ACALM1 | |
| SCHEMBL5504187 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1280495-A2 | 3-METHOXYBENZYL THIOUREA DERIVATIVES AND IMPROVED LIPID COMPOSITIONS CONTAINING SAME | Abbott, Thomas, P. (US) | 2003-02-05 | — | — | EP | claimed |
| WO-2001085681-A2 | 3-METHOXYBENZYL THIOUREA DERIVATIVES AND IMPROVED LIPID COMPOSITIONS CONTAINING SAME | THE FANNING CORPORATION (US) | 2001-11-15 | — | — | WO | claimed |
| WO-2019163829-A1 | ANTI-REFLECTION FILM AND LAYERED PRODUCT FILM HAVING ANTI-REFLECTION FILM | 三菱瓦斯化学株式会社 | 2019-08-29 | — | — | WO | disclosed |
| US-20100168084-A1 | Therapeutic compounds and related methods of use | ELIXIR PHARMACEUTICALS, INC. | 2010-07-01 | — | — | US | disclosed |
| WO-2008073451-A2 | BENZOIMIDAZOLE DERIVATIVES AS SIRTUIN (SIR) MODULATING COMPOUNDS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| EP-0804191-A1 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCERS USING INHIBITORS OF PLATELET DERIVED GROWTH RECEPTOR | Sugen, Inc. (US) | 1997-11-05 | — | — | EP | disclosed |
| WO-1995019169-A2 | TREATMENT OF PLATELET DERIVED GROWTH FACTOR RELATED DISORDERS SUCH AS CANCER USING INHIBITORS OF PLATELET DERIVED GROWTH FACTOR RECEPTOR | SUGEN, INC. (US) | 1995-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168084-A1 | Therapeutic compounds and related methods of use | EP300, KAT2A, KAT6B | BCL2 1672/4885BCL2L1 2489/4885ALOX5 1466/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.